New cell therapy, mammalian, and mRNA facility coming soon!
Our new AGC Biologics Yokohama facility is currently under construction and projected to be complete next year. The new facility will be just down the street from the AGC Yokohama Technical Center where cell therapy process development services will be begin in 2025.
Full process development services for mammalian, mRNA, and cell therapy are planned to start in the new facility in 2026 with full GMP manufacturing available in 2027.
Got a project? Let's talk.
Get all the details on this site
Our in-depth fact sheet provides all the details you need on the complete capabilities and services of this campus and its abilities to support your next project.
Yokohama fact sheetMammalian Manufacturing
We will offer one of the largest single-use bioreactors for a CDMO in Japan with multiple 5,000 L and 2,000 L bioreactors for mammalian cell culture.
Cell Therapy Manufacturing
This facility will offer capabilities for gene modification of cells by LVV/RVV and provide both autologous and allogeneic methods with GMP manufacturing scheduled to begin in 2027.
Global Capabilities
Messenger RNA Manufacturing
The new Yokohama facility is set to begin GMP mRNA manufacturing in 2027. It will feature production scales of up to 12.5 liters, as well as multiple purification and lipid nanoparticle (LNP) lines. This facility will benefit from shared best practices and decades of expertise drawn from our Heidelberg mRNA facility.
Process Development
Cell therapy process development services will be available in 2025 at our nearby AGC Yokohama Technical Center. Mammalian process development services are available at our Chiba facility. Full PD services, including mRNA will be available at the new facility by the end of 2026.
